Journal article
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Abstract
INTRODUCTION: First-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment of advanced non-small-cell lung cancer with EGFR-activating mutations improves outcomes compared with chemotherapy, but resistance develops in most patients. Compensatory signaling through type 1 insulin-like growth factor 1 receptor (IGF-1R) may contribute to resistance; dual blockade of IGF-1R and EGFR may improve outcomes.
PATIENTS AND …
Authors
Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn M-J; Chow LQM; Bazhenova L; Dechaphunkul A
Journal
Clinical Lung Cancer, Vol. 18, No. 1, pp. 34–42.e2
Publisher
Elsevier
Publication Date
January 2017
DOI
10.1016/j.cllc.2016.07.007
ISSN
1525-7304
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDouble-Blind MethodErbB ReceptorsErlotinib HydrochlorideFemaleFollow-Up StudiesHumansImidazolesLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingPrognosisPyrazinesSurvival Rate